368 related articles for article (PubMed ID: 33727667)
1. Safety of switching between rituximab biosimilars in onco-hematology.
Urru SAM; Spila Alegiani S; Guella A; Traversa G; Campomori A
Sci Rep; 2021 Mar; 11(1):5956. PubMed ID: 33727667
[TBL] [Abstract][Full Text] [Related]
2. Rituximab biosimilars in hematologic malignancies: the need for a real-world approach.
Nava-Parada P; Shelbaya A; Nabhan C
Future Oncol; 2020 Sep; 16(26):2017-2027. PubMed ID: 32598173
[TBL] [Abstract][Full Text] [Related]
3. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Lee S; Lee H; Kim E
BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
[TBL] [Abstract][Full Text] [Related]
5. Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA.
Shelbaya A; Kelton JM; Thompson J; Alvir JM; Maculaitis MC; Yang J
Future Oncol; 2021 Oct; 17(30):3941-3950. PubMed ID: 34259584
[TBL] [Abstract][Full Text] [Related]
6. Comparison of rituximab originator (MabThera
Perez T; Rico A; Boutière C; Maarouf A; Roudot M; Honoré S; Pelletier J; Bertault-Peres P; Audoin B
Mult Scler; 2021 Apr; 27(4):585-592. PubMed ID: 32180508
[TBL] [Abstract][Full Text] [Related]
7. Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan.
Halawah HH; Alkhatib NS; Almutairi AR; Saleh M; Halloush SS; Rashdan O; Masadh L; Abusara OH; Abraham I
J Med Econ; 2023; 26(1):835-842. PubMed ID: 37318242
[TBL] [Abstract][Full Text] [Related]
8. The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.
Brown JR; Cymbalista F; Sharman J; Jacobs I; Nava-Parada P; Mato A
Oncologist; 2018 Mar; 23(3):288-296. PubMed ID: 29212732
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study.
Mageau A; Bonnotte B; Ebbo M; Dossier A; Galicier L; Souchaud-Debouverie O; Orvain C; Gerfaud-Valentin M; Gobert D; Riviere E; Audia S; Mahevas M; Michel M; Viallard JF; Godeau B
Platelets; 2023 Dec; 34(1):2200848. PubMed ID: 37128870
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura.
Stubbs MJ; Low R; McGuckin S; Newton R; Thomas M; Westwood JP; Shah R; Cheesman S; Scully MA
Br J Haematol; 2019 Jun; 185(5):912-917. PubMed ID: 30919938
[TBL] [Abstract][Full Text] [Related]
11. Comparison of outcomes using the rituximab originator MabThera with the biosimilar Truxima in patients with ANCA-associated vasculitis.
Antonelou M; Abro A; Heath R; Iacovou A; Ashley C; Caplan J; Morgan MD; Logan S; Harper L; Salama AD
Scand J Rheumatol; 2022 Mar; 51(2):135-141. PubMed ID: 34474634
[TBL] [Abstract][Full Text] [Related]
12. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
Ogura M; Coiffier B; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
[TBL] [Abstract][Full Text] [Related]
15. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
Giuliani J; Bonetti A
Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
[TBL] [Abstract][Full Text] [Related]
17. Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience.
Bahap-Kara M; Duran E; Bayraktar-Ekincioglu A; Karadag O
Intern Emerg Med; 2023 Apr; 18(3):791-799. PubMed ID: 36826744
[TBL] [Abstract][Full Text] [Related]
18. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
[TBL] [Abstract][Full Text] [Related]
19. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden.
Di Giuseppe D; Lindstrom U; Bower H; Delcoigne B; Frisell T; Chatzidionysiou K; Sjöwall C; Lindqvist E; Askling J
Rheumatology (Oxford); 2022 Aug; 61(9):3596-3605. PubMed ID: 34919663
[TBL] [Abstract][Full Text] [Related]
20. Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany.
Otremba B; Borchardt J; Kuske A; Hollnagel-Schmitz M; Losch FO
Future Oncol; 2020 May; 16(15):1001-1012. PubMed ID: 32286864
[No Abstract] [Full Text] [Related]
[Next] [New Search]
